Nasdaq
$1.60▼ 2.44%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.21BShares out 7.600M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
9- 10.15After-hours26.10.16 05:078-KKey event#●●●#●●●
OPKO HEALTH, INC.Bullish
OPKO Health has entered into an asset purchase agreement to sell its clinical and anatomic pathology laboratory testing business, including the BioReference Health unit, to Laboratory Corporation of America Holdings for $722 million in cash. Additionally, the company is set to receive up to $150 million in cash over ten years based on future revenue from the 4Kscore prostate cancer test.…more
$1.60-2.44%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.2After-hours26.10.03 05:128-KKey event
OPKO HEALTH, INC.
OPKO Health announced that its 3.75% convertible senior notes, with approximately $121 million outstanding, are convertible into common stock through December 31, 2026, following the satisfaction of stock price triggers. The company will satisfy its conversion obligations by issuing common stock, with holders receiving at least 869.5652 shares per $1,000 principal amount.…more
$1.60-2.44%vs prev closeView filingShare - 8.28After-hours26.08.29 05:2410-Q/AEarnings
OPKO HEALTH, INC.
OPKO Health has filed its 10-Q report for the quarter ended June 30, 2026, disclosing its financial condition and operational results. CFO Adam Logal certified that the report complies with Securities Exchange Act requirements and fairly presents the company's financial status.…more
$1.60-2.44%vs prev closeView filingShare
8 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoRegular26.10.21 01:37Bullish#●●●#●●●
Myriad Genetics Sells Prenatal Unit to Labcorp for $210 Million
Myriad Genetics has agreed to sell its struggling prenatal health testing business to Labcorp for $210 million in an all-cash deal. The divestiture allows Myriad to offload a declining segment while Labcorp aims to integrate these assets to drive future diagnostic revenue.…more
$1.60-2.44%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.15Regular26.10.16 00:41
●●●●●●●● ●●●●● ●●●●●●
OPKO Health has agreed to sell select assets of its BioReference Health diagnostics business to Labcorp for up to $872 million. This divestiture allows OPKO to focus on its core biopharmaceutical business while streamlining operations.…more
$1.60-2.44%vs prev closeShareBenzinga - 10.15Pre-market26.10.15 20:33
●●●●●●●● ●●●●● ●●●●●●
Labcorp has entered into an agreement to acquire select assets from OPKO Health's subsidiary, BioReference Health. The financial terms of the transaction were not disclosed.…more
$1.60-2.44%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report